Ingalls & Snyder LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 9.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,603 shares of the conglomerate’s stock after buying an additional 138 shares during the quarter. Ingalls & Snyder LLC’s holdings in Danaher were worth $232,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. MBM Wealth Consultants LLC boosted its position in Danaher by 2.0% during the second quarter. MBM Wealth Consultants LLC now owns 3,701 shares of the conglomerate’s stock valued at $529,000 after acquiring an additional 74 shares during the last quarter. Mechanics Bank Trust Department raised its holdings in shares of Danaher by 1.7% during the second quarter. Mechanics Bank Trust Department now owns 4,384 shares of the conglomerate’s stock valued at $627,000 after purchasing an additional 75 shares during the period. Copperwynd Financial LLC raised its holdings in shares of Danaher by 1.9% in the 2nd quarter. Copperwynd Financial LLC now owns 4,144 shares of the conglomerate’s stock worth $592,000 after acquiring an additional 79 shares during the last quarter. Lincoln National Corp raised its holdings in shares of Danaher by 3.1% in the 2nd quarter. Lincoln National Corp now owns 2,666 shares of the conglomerate’s stock worth $381,000 after acquiring an additional 81 shares during the last quarter. Finally, Meridian Financial Partners LLC raised its holdings in shares of Danaher by 3.0% in the 2nd quarter. Meridian Financial Partners LLC now owns 2,847 shares of the conglomerate’s stock worth $411,000 after acquiring an additional 83 shares during the last quarter. 78.30% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Chairman Mitchell P. Rales bought 2,500 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $139.52 per share, with a total value of $348,800.00. Following the purchase, the chairman now owns 3,030,453 shares of the company’s stock, valued at approximately $422,808,802.56. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 11.40% of the company’s stock.
NYSE:DHR traded up $0.73 during trading hours on Friday, reaching $135.23. The company’s stock had a trading volume of 1,633,369 shares, compared to its average volume of 2,487,994. The firm has a market capitalization of $95.87 billion, a price-to-earnings ratio of 29.92, a PEG ratio of 2.24 and a beta of 0.92. The firm has a 50-day simple moving average of $139.07 and a 200-day simple moving average of $138.28. Danaher Co. has a 1 year low of $94.59 and a 1 year high of $147.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.09 and a current ratio of 3.43.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, October 24th. The conglomerate reported $1.16 EPS for the quarter, topping analysts’ consensus estimates of $1.15 by $0.01. The company had revenue of $5.04 billion for the quarter, compared to analysts’ expectations of $5.02 billion. Danaher had a net margin of 12.13% and a return on equity of 11.42%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.10 EPS. Equities analysts anticipate that Danaher Co. will post 4.76 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend was Thursday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 15.04%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.